Oncolytics Biotech Secures Third Fast Track Designation for Pelareorep, This Time in Anal Cancer
ONCY is trading near its 52-week low of $0.77 (12% above the low).
Summary
Oncolytics Biotech received FDA Fast Track designation for pelareorep in second-line and later anal cancer, its third such designation in gastrointestinal cancers, supported by strong clinical data and a clear path to a pivotal study.
Key Events · Product Development and Regulatory · ONCY
-
Third Fast Track Designation
The FDA granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer (SCAC), adding to prior designations in colorectal and pancreatic cancer.
-
Regulatory Benefits
The designation enables rolling review of a future Biologics License Application, more frequent FDA interactions, and eligibility for Priority Review, potentially accelerating the path to market.
-
Strong Clinical Data
Results from the GOBLET study show a 30% objective response rate, a 15.5-month median duration of response, and 82% 12-month overall survival, more than doubling historical benchmarks in this setting.
-
Clear Pivotal Path
Based on April 2026 FDA feedback, Oncolytics believes it has a clear regulatory framework to advance pelareorep into a pivotal study for anal cancer, de-risking the program.
Analysis · ONCY · Life Sciences
The FDA has granted Fast Track designation to pelareorep for second-line and later anal cancer, a setting with no approved therapies after first-line progression. This marks the third Fast Track in gastrointestinal cancers, following colorectal and pancreatic designations, and unlocks rolling review and Priority Review eligibility. Supporting data from the GOBLET study show a 30% objective response rate—more than double historical benchmarks—and a median duration of response of 15.5 months. With a clear regulatory framework now in place, Oncolytics is positioned to advance toward a pivotal study, de-risking the program and strengthening its path to registration in a market estimated at $1 billion annually.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1179 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.8M. The 52-week trading range was $0.77 to $1.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.